Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 701–710 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 701
- Medicine slug
- griseofulvin
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 9
- Source count
- 6
- Agreement rate
- 1
- Recorded readings
9 to 24 hours
- Numeric value
- 9
- Unit
- hours
- Source records
- 6
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 6 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:98829d90-b289-4bec-a625-7af412a5cb2d (opens source in a new tab)
Griseofulvin label
Version not recorded · Effective date not recorded
Griseofulvin has a variable elimination half-life in plasma (9 to 24 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6902a976-b0c5-48a4-8d50-984002be6c3a (opens source in a new tab)
Griseofulvin label
Version not recorded · Effective date not recorded
Griseofulvin has a variable elimination half-life in plasma (9 to 24 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5bafb97f-621b-4b96-a787-68e0bb5c8637 (opens source in a new tab)
Griseofulvin label
Version not recorded · Effective date not recorded
Griseofulvin has a variable elimination half-life in plasma (9 to 24 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1c26d7a6-17d9-4a95-a4ee-cfc5fe6bb95d (opens source in a new tab)
Griseofulvin label
Version not recorded · Effective date not recorded
Griseofulvin has a variable elimination half-life in plasma (9 to 24 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:af318d5d-cc39-4a63-a590-b87c50f2694f (opens source in a new tab)
Griseofulvin label
Version not recorded · Effective date not recorded
Griseofulvin has a variable elimination half-life in plasma (9 to 24 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:67e3ba3c-77e1-43b5-a93c-5bf5e3855780 (opens source in a new tab)
Griseofulvin label
Version not recorded · Effective date not recorded
Griseofulvin has a variable elimination half-life in plasma (9 to 24 hours).
Projected row 702
- Medicine slug
- guanfacine
- Compared field
- bioavailability
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 58
- Source count
- 32
- Agreement rate
- 0.75
- Recorded readings
80 %
- Numeric value
- 80
- Unit
- %
- Source records
- 24
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 24 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4973deb3-57ec-1ef3-e063-6294a90aa035 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
Pharmacokinetics Relative to an intravenous dose of 3 mg, the absolute oral bioavailability of guanfacine is about 80 %.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4f1e668a-37dd-44f4-ae99-3a1f6dba3eea (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
Pharmacokinetics Relative to an intravenous dose of 3 mg, the absolute oral bioavailability of guanfacine is about 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:04a3bd2d-9a9c-43e8-a0e2-280e02265f16 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
Pharmacokinetics Relative to an intravenous dose of 3 mg, the absolute oral bioavailability of guanfacine is about 80 %.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a0c2d95d-805c-4c7d-9733-52073a65218a (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
Pharmacokinetics Relative to an intravenous dose of 3 mg, the absolute oral bioavailability of guanfacine is about 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4248d53e-4dc3-452b-96f8-5d715c254c26 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
Pharmacokinetics Relative to an intravenous dose of 3 mg, the absolute oral bioavailability of guanfacine is about 80 %.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:73d50917-c807-4213-8efe-aea209845936 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
Pharmacokinetics Relative to an intravenous dose of 3 mg, the absolute oral bioavailability of guanfacine is about 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a81b956b-f004-4426-ba20-375ccf21eb71 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
Pharmacokinetics: Relative to an intravenous dose of 3 mg, the absolute oral bioavailability of guanfacine is about 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fa7ae501-ee34-4e50-9052-7952e36bbd0e (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
Pharmacokinetics Relative to an intravenous dose of 3 mg, the absolute oral bioavailability of guanfacine is about 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:83d0739b-46fd-6228-e85c-089611067a35 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
Pharmacokinetics Relative to an intravenous dose of 3 mg, the absolute oral bioavailability of guanfacine is about 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ba089e4c-8623-4159-8230-5c7fd02cdb12 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
Pharmacokinetics Relative to an intravenous dose of 3 mg, the absolute oral bioavailability of guanfacine is about 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:830c0be8-2137-46ee-94c6-aa048b7de35f (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
Pharmacokinetics Relative to an intravenous dose of 3 mg, the absolute oral bioavailability of guanfacine is about 80 %.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:09442806-db7b-49de-8ffc-e4cb83138349 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
Pharmacokinetics Relative to an intravenous dose of 3 mg, the absolute oral bioavailability of guanfacine is about 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1b1063ba-fee3-4540-9139-db4b915f82e2 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
Pharmacokinetics Relative to an intravenous dose of 3 mg, the absolute oral bioavailability of guanfacine is about 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e6d4fc3d-4169-44f1-bcb9-1188de40d4e5 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
Pharmacokinetics Relative to an intravenous dose of 3 mg, the absolute oral bioavailability of guanfacine is about 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a80dfdc4-b9a7-4f8e-af67-dea30bc063ac (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
Pharmacokinetics Relative to an intravenous dose of 3 mg, the absolute oral bioavailability of guanfacine is about 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fac4a4c2-f5f0-46ef-b76b-315abe9136fa (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
Pharmacokinetics Relative to an intravenous dose of 3 mg, the absolute oral bioavailability of guanfacine is about 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9fdc4b4-5b00-46dd-8700-6e36ceaafb0e (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
Pharmacokinetics Relative to an intravenous dose of 3 mg, the absolute oral bioavailability of guanfacine is about 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:87e1ad56-a7b9-431d-a5d2-d52fb64735c7 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
Pharmacokinetics Relative to an intravenous dose of 3 mg, the absolute oral bioavailability of guanfacine is about 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cc3cc6de-583c-4180-9f4c-9e4c75eb6f38 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
Pharmacokinetics Relative to an intravenous dose of 3 mg, the absolute oral bioavailability of guanfacine is about 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c38bf26f-8a98-4baa-9abb-c83f812900a1 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
Pharmacokinetics Relative to an intravenous dose of 3 mg, the absolute oral bioavailability of guanfacine is about 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:266c6819-cd71-55d0-e063-6394a90ab157 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
Pharmacokinetics Relative to an intravenous dose of 3 mg, the absolute oral bioavailability of guanfacine is about 80 %.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:400be431-ad6c-4783-a513-ca8b47bf43ee (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
Pharmacokinetics Relative to an intravenous dose of 3 mg, the absolute oral bioavailability of guanfacine is about 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9f967d68-5aff-4955-8c79-69febf7c38ad (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
Pharmacokinetics Relative to an intravenous dose of 3 mg, the absolute oral bioavailability of guanfacine is about 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:14146031-8d56-469b-8de8-fe3cf1712e78 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
Pharmacokinetics Relative to an intravenous dose of 3 mg, the absolute oral bioavailability of guanfacine is about 80%.
58%
- Numeric value
- 58
- Unit
- %
- Source records
- 8
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 8 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:187bd24b-d69b-4cdf-be4a-c89e9b131b81 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
Therefore, the relative bioavailability of the extended-release to immediate-release guanfacine is 58%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1c5d9514-641a-4c72-a79a-96a0fe5d6fbd (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
Therefore, the relative bioavailability of the extended-release to immediate-release guanfacine is 58%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b972af81-3a37-40be-9fe1-3ddf59852528 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
Therefore, the relative bioavailability of INTUNIV to immediate-release guanfacine is 58%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:07cda4a1-0eb5-491e-8d16-4e6a6feb93ac (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
Therefore, the relative bioavailability of the extended-release to immediate-release guanfacine is 58%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:07797c4a-a799-436b-a77c-a2861a811a99 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
Therefore, the relative bioavailability of the extended-release to immediate-release guanfacine is 58%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:178b649f-8c0f-4fea-a168-3ce4ff52129d (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
Therefore, the relative bioavailability of the extended-release to immediate-release guanfacine is 58%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8348e63a-5cbc-489e-b7bf-046c65ba2e8e (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
Therefore, the relative bioavailability of the extended-release to immediate-release guanfacine is 58%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1c492e87-3406-ddb8-aaf2-e609c2ded503 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
Therefore, the relative bioavailability of the extended-release to immediate-release guanfacine is 58%.
Projected row 703
- Medicine slug
- guanfacine
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 58
- Source count
- 24
- Agreement rate
- 1
- Recorded readings
17 hours
- Numeric value
- 17
- Unit
- hours
- Source records
- 24
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 24 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4973deb3-57ec-1ef3-e063-6294a90aa035 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
In individuals with normal renal function, the average elimination half-life is approximately 17 hours (range 10 hours to 30 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4f1e668a-37dd-44f4-ae99-3a1f6dba3eea (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
In individuals with normal renal function, the average elimination half-life is approximately 17 hr (range 10 - 30 hr).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:04a3bd2d-9a9c-43e8-a0e2-280e02265f16 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
In individuals with normal renal function, the average elimination half-life is approximately 17 hours (range 10 hours to 30 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a0c2d95d-805c-4c7d-9733-52073a65218a (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
In individuals with normal renal function, the average elimination half-life is approximately 17 hr (range 10 to 30 hr).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4248d53e-4dc3-452b-96f8-5d715c254c26 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
In individuals with normal renal function, the average elimination half-life is approximately 17 hours (range 10 hours to 30 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:73d50917-c807-4213-8efe-aea209845936 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
In individuals with normal renal function, the average elimination half-life is approximately 17 hours (range 10 hours to 30 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a81b956b-f004-4426-ba20-375ccf21eb71 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
In individuals with normal renal function, the average elimination half-life is approximately 17 hr (range 10 to 30 hr).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fa7ae501-ee34-4e50-9052-7952e36bbd0e (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
In individuals with normal renal function, the average elimination half-life is approximately 17 hr (range 10 to 30 hr).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:83d0739b-46fd-6228-e85c-089611067a35 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
In individuals with normal renal function, the average elimination half-life is approximately 17 hr (range 10 to 30 hr).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ba089e4c-8623-4159-8230-5c7fd02cdb12 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
In individuals with normal renal function, the average elimination half-life is approximately 17 hr (range 10-30 hr).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:830c0be8-2137-46ee-94c6-aa048b7de35f (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
In individuals with normal renal function, the average elimination half-life is approximately 17 hours (range 10 hours to 30 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:09442806-db7b-49de-8ffc-e4cb83138349 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
In individuals with normal renal function, the average elimination half-life is approximately 17 hr (range 10-30 hr).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1b1063ba-fee3-4540-9139-db4b915f82e2 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
In individuals with normal renal function, the average elimination half-life is approximately 17 hr (range 10 to 30 hr).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e6d4fc3d-4169-44f1-bcb9-1188de40d4e5 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
In individuals with normal renal function, the average elimination half-life is approximately 17 hr (range 10 to 30 hr).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a80dfdc4-b9a7-4f8e-af67-dea30bc063ac (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
In individuals with normal renal function, the average elimination half-life is approximately 17 hours (range 10 hours to 30 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fac4a4c2-f5f0-46ef-b76b-315abe9136fa (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
In individuals with normal renal function, the average elimination half-life is approximately 17 hr (range 10-30 hr).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9fdc4b4-5b00-46dd-8700-6e36ceaafb0e (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
In individuals with normal renal function, the average elimination half-life is approximately 17 hr (range 10 to 30 hr).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:87e1ad56-a7b9-431d-a5d2-d52fb64735c7 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
In individuals with normal renal function, the average elimination half-life is approximately 17 hr (range 10 - 30 hr).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cc3cc6de-583c-4180-9f4c-9e4c75eb6f38 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
In individuals with normal renal function, the average elimination half-life is approximately 17 hr (range 10 to 30 hr).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c38bf26f-8a98-4baa-9abb-c83f812900a1 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
In individuals with normal renal function, the average elimination half-life is approximately 17 hr (range 10 to 30 hr).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:266c6819-cd71-55d0-e063-6394a90ab157 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
In individuals with normal renal function, the average elimination half-life is approximately 17 hours (range 10 hours to 30 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:400be431-ad6c-4783-a513-ca8b47bf43ee (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
In individuals with normal renal function, the average elimination half-life is approximately 17 hr (range 10-30 hr).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9f967d68-5aff-4955-8c79-69febf7c38ad (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
In individuals with normal renal function, the average elimination half-life is approximately 17 hours (range 10 hours to 30 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:14146031-8d56-469b-8de8-fe3cf1712e78 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
In individuals with normal renal function, the average elimination half-life is approximately 17 hr (range 10 to 30 hr).
Projected row 704
- Medicine slug
- guanfacine
- Compared field
- tMax
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 58
- Source count
- 58
- Agreement rate
- 0.586207
- Recorded readings
5 hours
- Numeric value
- 5
- Unit
- hours
- Source records
- 34
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 34 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e16beec7-9acd-4cd1-be5c-b666ad7d2430 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
After oral administration of guanfacine extended-release tablets the time to peak plasma concentration is approximately 5 hours in children and adolescents with ADHD.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:145a191d-9049-4014-9c42-503fdde063dc (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
After oral administration of guanfacine extended-release tablets the time to peak plasma concentration is approximately 5 hours in children and adolescents with ADHD.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6460ad33-4feb-4a4d-9958-501084046389 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
After oral administration of guanfacine extended-release tablets the time to peak plasma concentration is approximately 5 hours in children and adolescents with ADHD.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:35d3c996-1755-c017-e063-6294a90abc1f (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
After oral administration of guanfacine the time to peak plasma concentration is approximately 5 hours in children and adolescents with ADHD.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ab2e3597-14fc-4614-ae87-0d1d18188a68 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
After oral administration of guanfacine extended-release tablets the time to peak plasma concentration is approximately 5 hours in children and adolescents with ADHD.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3a171942-37af-430d-8b9d-bb678ca2be4b (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
After oral administration of guanfacine extended-release the time to peak plasma concentration is approximately 5 hours in children and adolescents with ADHD.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0b2afdab-8c92-463e-9734-f2c8b4200777 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
After oral administration of guanfacine extended-release tablets the time to peak plasma concentration is approximately 5 hours in children and adolescents with ADHD.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:187bd24b-d69b-4cdf-be4a-c89e9b131b81 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
After oral administration of guanfacine extended-release tablets the time to peak plasma concentration is approximately 5 hours in children and adolescents with ADHD.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9db7def2-c6f9-4d7d-a403-fc615358913a (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
After oral administration of guanfacine the time to peak plasma concentration is approximately 5 hours in children and adolescents with ADHD.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:261c06ce-8708-d659-e063-6294a90ac381 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
After oral administration of guanfacine extended-release tablets the time to peak plasma concentration is approximately 5 hours in children and adolescents with ADHD.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c20cc7eb-9de5-407a-8943-c4d2e3f78444 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
After oral administration of guanfacine extended-release tablets the time to peak plasma concentration is approximately 5 hours in children and adolescents with ADHD.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6e16cf54-c0d7-47ea-b502-c2146fd87f23 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
After oral administration of guanfacine extended-release tablets the time to peak plasma concentration is approximately 5 hours in children and adolescents with ADHD.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1c5d9514-641a-4c72-a79a-96a0fe5d6fbd (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
After oral administration of guanfacine extended-release tablets the time to peak plasma concentration is approximately 5 hours in children and adolescents with ADHD.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4b86e1c1-9cbe-d4a9-e063-6294a90a2274 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
After oral administration of guanfacine the time to peak plasma concentration is approximately 5 hours in children and adolescents with ADHD.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57b8ad03-a5d1-4218-8d3a-40b211da84e6 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
After oral administration of guanfacine extended-release tablets the time to peak plasma concentration is approximately 5 hours in children and adolescents with ADHD.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b972af81-3a37-40be-9fe1-3ddf59852528 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
After oral administration of INTUNIV the time to peak plasma concentration is approximately 5 hours in children and adolescents with ADHD.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:07cda4a1-0eb5-491e-8d16-4e6a6feb93ac (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
After oral administration of guanfacine extended-release tablets the time to peak plasma concentration is approximately 5 hours in children and adolescents with ADHD.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f070a54a-2738-4ef2-a98a-f9e7a7a56f55 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
After oral administration of guanfacine extended-release tablets the time to peak plasma concentration is approximately 5 hours in children and adolescents with ADHD.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f4e3c976-8811-4388-92b3-d248d705f8b1 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
After oral administration of guanfacine extended-release tablets the time to peak plasma concentration is approximately 5 hours in children and adolescents with ADHD.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3ec4fed6-cafc-49a0-9540-8d70ac435769 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
After oral administration of guanfacine extended-release tablets the time to peak plasma concentration is approximately 5 hours in children and adolescents with ADHD.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ba58a5d0-607b-4dca-a63e-92d8dd81d81b (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
After oral administration of guanfacine extended-release tablets the time to peak plasma concentration is approximately 5 hours in children and adolescents with ADHD.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:07a701e2-39b7-4bb1-a7c7-d9baed4ab18a (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
After oral administration of guanfacine extended-release tablets the time to peak plasma concentration is approximately 5 hours in children and adolescents with ADHD.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6006df06-0448-462d-b81e-7add50a6d71b (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
After oral administration of guanfacine extended-release tablets the time to peak plasma concentration is approximately 5 hours in children and adolescents with ADHD.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:07797c4a-a799-436b-a77c-a2861a811a99 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
After oral administration of guanfacine extended-release tablets the time to peak plasma concentration is approximately 5 hours in children and adolescents with ADHD.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0836a1d5-f1fc-4b94-9667-667278a74c93 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
After oral administration of guanfacine the time to peak plasma concentration is approximately 5 hours in children and adolescents with ADHD.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:983b3157-cbea-435d-ba32-9ee7ef95226a (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
After oral administration of guanfacine the time to peak plasma concentration is approximately 5 hours in children and adolescents with ADHD.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d0a0f8e-5098-4ee2-a4ee-d026789923e2 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
After oral administration of guanfacine extended-release tablets the time to peak plasma concentration is approximately 5 hours in children and adolescents with ADHD.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7db29f50-df23-49b1-ad92-05c42fda4ccd (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
After oral administration of guanfacine the time to peak plasma concentration is approximately 5 hours in children and adolescents with ADHD.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ed65ca51-b9b0-43b9-9826-03a7be256a2a (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
After oral administration of guanfacine extended-release tablets the time to peak plasma concentration is approximately 5 hours in children and adolescents with ADHD.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:36fd53a6-7006-4955-a3cd-b1c08cf84d6c (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
After oral administration of guanfacine extended-release tablets the time to peak plasma concentration is approximately 5 hours in children and adolescents with ADHD.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:178b649f-8c0f-4fea-a168-3ce4ff52129d (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
After oral administration of guanfacine extended-release tablets the time to peak plasma concentration is approximately 5 hours in children and adolescents with ADHD.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9d558d8e-8b55-41c6-8209-62b1f7bb0dd4 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
After oral administration of guanfacine extended-release tablets the time to peak plasma concentration is approximately 5 hours in children and adolescents with ADHD.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8348e63a-5cbc-489e-b7bf-046c65ba2e8e (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
After oral administration of guanfacine extended-release tablets the time to peak plasma concentration is approximately 5 hours in children and adolescents with ADHD.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1c492e87-3406-ddb8-aaf2-e609c2ded503 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
After oral administration of guanfacine extended-release tablets the time to peak plasma concentration is approximately 5 hours in children and adolescents with ADHD.
2.6 hours
- Numeric value
- 2.6
- Unit
- hours
- Source records
- 24
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 24 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4973deb3-57ec-1ef3-e063-6294a90aa035 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur from 1 hour to 4 hours with an average of 2.6 hours after single oral doses or at steady state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4f1e668a-37dd-44f4-ae99-3a1f6dba3eea (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur from 1 to 4 hours with an average of 2.6 hours after single oral doses or at steady state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:04a3bd2d-9a9c-43e8-a0e2-280e02265f16 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur from 1 hour to 4 hours with an average of 2.6 hours after single oral doses or at steady state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a0c2d95d-805c-4c7d-9733-52073a65218a (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur from 1 to 4 hours with an average of 2.6 hours after single oral doses or at steady-state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4248d53e-4dc3-452b-96f8-5d715c254c26 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur from 1 hour to 4 hours with an average of 2.6 hours after single oral doses or at steady state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:73d50917-c807-4213-8efe-aea209845936 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur from 1 hours to 4 hours with an average of 2.6 hours after single oral doses or at steady-state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a81b956b-f004-4426-ba20-375ccf21eb71 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur from 1 to 4 hours with an average of 2.6 hours after single oral doses or at steady state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fa7ae501-ee34-4e50-9052-7952e36bbd0e (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur from 1 to 4 hours with an average of 2.6 hours after single oral doses or at steady-state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:83d0739b-46fd-6228-e85c-089611067a35 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur from 1 to 4 hours with an average of 2.6 hours after single oral doses or at steady state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ba089e4c-8623-4159-8230-5c7fd02cdb12 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur from 1 to 4 hours with an average of 2.6 hours after single oral doses or at steady state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:830c0be8-2137-46ee-94c6-aa048b7de35f (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur from 1 hour to 4 hours with an average of 2.6 hours after single oral doses or at steady state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:09442806-db7b-49de-8ffc-e4cb83138349 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur from 1 to 4 hours with an average of 2.6 hours after single oral doses or at steady state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1b1063ba-fee3-4540-9139-db4b915f82e2 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur from 1 to 4 hours with an average of 2.6 hours after single oral doses or at steady state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e6d4fc3d-4169-44f1-bcb9-1188de40d4e5 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur from 1 to 4 hours with an average of 2.6 hours after single oral doses or at steady state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a80dfdc4-b9a7-4f8e-af67-dea30bc063ac (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur from 1 hours to 4 hours with an average of 2.6 hours after single oral doses or at steady-state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fac4a4c2-f5f0-46ef-b76b-315abe9136fa (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur from 1 to 4 hours with an average of 2.6 hours after single oral doses or at steady state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9fdc4b4-5b00-46dd-8700-6e36ceaafb0e (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur from 1 to 4 hours with an average of 2.6 hours after single oral doses or at steady-state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:87e1ad56-a7b9-431d-a5d2-d52fb64735c7 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur from 1 to 4 hours with an average of 2.6 hours after single oral doses or at steady state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cc3cc6de-583c-4180-9f4c-9e4c75eb6f38 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur from 1 to 4 hours with an average of 2.6 hours after single oral doses or at steady-state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c38bf26f-8a98-4baa-9abb-c83f812900a1 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur from 1 to 4 hours with an average of 2.6 hours after single oral doses or at steady state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:266c6819-cd71-55d0-e063-6394a90ab157 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur from 1 hour to 4 hours with an average of 2.6 hours after single oral doses or at steady state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:400be431-ad6c-4783-a513-ca8b47bf43ee (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur from 1 to 4 hours with an average of 2.6 hours after single oral doses or at steady state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9f967d68-5aff-4955-8c79-69febf7c38ad (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur from 1 hours to 4 hours with an average of 2.6 hours after single oral doses or at steady-state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:14146031-8d56-469b-8de8-fe3cf1712e78 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
Peak plasma concentrations occur from 1 to 4 hours with an average of 2.6 hours after single oral doses or at steady state.
Projected row 705
- Medicine slug
- guanfacine
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 58
- Source count
- 24
- Agreement rate
- 1
- Recorded readings
6.3 L/kg
- Numeric value
- 6.3
- Unit
- L/kg
- Source records
- 24
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 24 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4973deb3-57ec-1ef3-e063-6294a90aa035 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
The whole body volume of distribution is high (a mean of 6.3 L/kg), which suggests a high distribution of drug to the tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4f1e668a-37dd-44f4-ae99-3a1f6dba3eea (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
The whole body volume of distribution is high (a mean of 6.3 L/kg), which suggests a high distribution of drug to the tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:04a3bd2d-9a9c-43e8-a0e2-280e02265f16 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
The whole body volume of distribution is high (a mean of 6.3 L/kg), which suggests a high distribution of drug to the tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a0c2d95d-805c-4c7d-9733-52073a65218a (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
The whole body volume of distribution is high (a mean of 6.3 L/kg), which suggests a high distribution of drug to the tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4248d53e-4dc3-452b-96f8-5d715c254c26 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
The whole body volume of distribution is high (a mean of 6.3 L/kg), which suggests a high distribution of drug to the tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:73d50917-c807-4213-8efe-aea209845936 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
The whole body volume of distribution is high (a mean of 6.3 L/kg), which suggests a high distribution of drug to the tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a81b956b-f004-4426-ba20-375ccf21eb71 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
The whole body volume of distribution is high (a mean of 6.3 L/kg), which suggests a high distribution of drug to the tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fa7ae501-ee34-4e50-9052-7952e36bbd0e (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
The whole body volume of distribution is high (a mean of 6.3 L/kg), which suggests a high distribution of drug to the tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:83d0739b-46fd-6228-e85c-089611067a35 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
The whole body volume of distribution is high (a mean of 6.3 L/kg), which suggests a high distribution of drug to the tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ba089e4c-8623-4159-8230-5c7fd02cdb12 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
The whole body volume of distribution is high (a mean of 6.3 L/kg), which suggests a high distribution of drug to the tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:830c0be8-2137-46ee-94c6-aa048b7de35f (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
The whole body volume of distribution is high (a mean of 6.3 L/kg), which suggests a high distribution of drug to the tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:09442806-db7b-49de-8ffc-e4cb83138349 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
The whole body volume of distribution is high (a mean of 6.3 L/kg), which suggests a high distribution of drug to the tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1b1063ba-fee3-4540-9139-db4b915f82e2 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
The whole body volume of distribution is high (a mean of 6.3 L/kg), which suggests a high distribution of drug to the tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e6d4fc3d-4169-44f1-bcb9-1188de40d4e5 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
The whole body volume of distribution is high (a mean of 6.3 L/kg), which suggests a high distribution of drug to the tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a80dfdc4-b9a7-4f8e-af67-dea30bc063ac (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
The whole body volume of distribution is high (a mean of 6.3 L/kg), which suggests a high distribution of drug to the tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fac4a4c2-f5f0-46ef-b76b-315abe9136fa (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
The whole body volume of distribution is high (a mean of 6.3 L/kg), which suggests a high distribution of drug to the tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9fdc4b4-5b00-46dd-8700-6e36ceaafb0e (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
The whole body volume of distribution is high (a mean of 6.3 L/kg), which suggests a high distribution of drug to the tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:87e1ad56-a7b9-431d-a5d2-d52fb64735c7 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
The whole body volume of distribution is high (a mean of 6.3 L/kg), which suggests a high distribution of drug to the tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cc3cc6de-583c-4180-9f4c-9e4c75eb6f38 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
The whole body volume of distribution is high (a mean of 6.3 L/kg), which suggests a high distribution of drug to the tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c38bf26f-8a98-4baa-9abb-c83f812900a1 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
The whole body volume of distribution is high (a mean of 6.3 L/kg), which suggests a high distribution of drug to the tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:266c6819-cd71-55d0-e063-6394a90ab157 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
The whole body volume of distribution is high (a mean of 6.3 L/kg), which suggests a high distribution of drug to the tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:400be431-ad6c-4783-a513-ca8b47bf43ee (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
The whole body volume of distribution is high (a mean of 6.3 L/kg), which suggests a high distribution of drug to the tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9f967d68-5aff-4955-8c79-69febf7c38ad (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
The whole body volume of distribution is high (a mean of 6.3 L/kg), which suggests a high distribution of drug to the tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:14146031-8d56-469b-8de8-fe3cf1712e78 (opens source in a new tab)
Guanfacine label
Version not recorded · Effective date not recorded
The whole body volume of distribution is high (a mean of 6.3 L/kg), which suggests a high distribution of drug to the tissues.
Projected row 706
- Medicine slug
- heparin
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 58
- Source count
- 53
- Agreement rate
- 1
- Recorded readings
0.5 to 2 h
- Numeric value
- 0.5
- Unit
- hours
- Source records
- 53
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 53 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:feec2820-502f-4a97-84c9-f173729c51d3 (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The plasma half-life is dose-dependent and it ranges from 0.5 to 2 h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8ebe4b4d-cb28-47e8-9598-6105d250b3d2 (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The plasma half-life is dose-dependent and it ranges from 0.5 to 2 h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6be171fb-c85f-4336-a88d-b4d97bb0fe03 (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The plasma half-life is dose-dependent and it ranges from 0.5 to 2 h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9a5549ae-527a-1b83-e053-2a95a90a133d (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The plasma half-life is dose-dependent and it ranges from 0.5 to 2 h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7df6c90c-3b55-4bb6-8a72-6e6a6aca4e7c (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The plasma half-life is dose-dependent and it ranges from 0.5 to 2 h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32e34077-aff1-4ec7-f9b0-b8e240768fb8 (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The plasma half-life is dose-dependent and it ranges from 0.5 to 2 h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6d5eae7d-a5f6-411c-b589-3e5f7eecc875 (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The plasma half-life is dose-dependent and it ranges from 0.5 to 2 h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a120bdfd-21e1-4024-82a7-13cfeed290c1 (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The plasma half-life is dose-dependent and it ranges from 0.5 to 2 h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cece935c-1c0a-4949-b023-d6df3d53fbfa (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The plasma half-life is dose-dependent and it ranges from 0.5 to 2 h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:295ea9c6-d08c-40f0-a908-de0fdac44644 (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The plasma half-life is dose-dependent and it ranges from 0.5 to 2 h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1e362730-5a56-4948-a90f-2cb75fed9e91 (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The plasma half-life is dose-dependent and it ranges from 0.5 to 2 h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ef309d83-7262-4874-8580-f4ca254f963a (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The plasma half-life is dose-dependent and it ranges from 0.5 to 2 h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:83a59e7d-63e9-4eb8-87f0-52039d6893a5 (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The plasma half-life is dose-dependent and it ranges from 0.5 to 2 h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4deaa9ac-91aa-d96b-e063-6294a90a47bd (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The plasma half-life is dose-dependent and it ranges from 0.5 to 2 h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51197aa6-de34-3a55-e063-6294a90a89c9 (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The plasma half-life is dose-dependent, and it ranges from 0.5 to 2 h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e0cc5f44-9a67-4274-a48a-d6118e96d391 (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The plasma half-life is dose-dependent and it ranges from 0.5 to 2 h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c8c4edd2-ee9e-4558-6b8c-b83adc242a0a (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The plasma half-life is dose-dependent and it ranges from 0.5 to 2 h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ad0f410c-6121-43f9-9844-943472961cb0 (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The plasma half-life is dose-dependent and it ranges from 0.5 to 2 h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2edf6d35-5cf3-b7ff-e063-6394a90a4f33 (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The plasma half-life is dose-dependent and it ranges from 0.5 to 2 h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:62cfd1bb-894f-4429-b362-1e40981dccc6 (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The plasma half-life is dose-dependent and it ranges from 0.5 to 2 h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2a173253-dfdc-4d9d-8dee-b9c13e6fa9f5 (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The plasma half-life is dose-dependent and it ranges from 0.5 to 2 h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a5fab0b1-c472-489c-ba87-2f8e53356173 (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The plasma half-life is dose-dependent and it ranges from 0.5 to 2 h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:07438e10-1589-4683-9f26-e5494d076cf0 (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The plasma half-life is dose-dependent and it ranges from 0.5 to 2 h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:301b19bc-21c2-4a35-9d29-569b08d855c4 (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The plasma half-life is dose-dependent and it ranges from 0.5 to 2 h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57f1ec87-8a7d-41da-b8b8-9ecc8601c60f (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The plasma half-life is dose-dependent and it ranges from 0.5 to 2 h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:34b8fe93-ee34-4a35-9af5-5d41705a28e9 (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The plasma half-life is dose-dependent and it ranges from 0.5 to 2 h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3ea2bd53-ed13-a516-e063-6394a90a5dd9 (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The plasma half-life is dose-dependent and it ranges from 0.5 to 2 h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3edf9198-b88d-7808-e063-6394a90ae89c (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The plasma half-life is dose-dependent and it ranges from 0.5 to 2 h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7f05762a-7527-4796-b21e-68277aec379e (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The plasma half-life is dose-dependent and it ranges from 0.5 to 2 h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56dc3074-f1c5-45a3-b923-f1d14858e06d (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The plasma half-life is dose-dependent and it ranges from 0.5 to 2 h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3a998729-c912-4e21-8e49-d1e72ba6fe9e (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The plasma half-life is dose-dependent and it ranges from 0.5 to 2 h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f67eea4e-80ff-48da-8b04-8addc5cd31d1 (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The plasma half-life is dose-dependent and it ranges from 0.5 to 2 h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0d929726-76c3-48fc-b4e7-fd06409f9fb3 (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The plasma half-life is dose-dependent, and it ranges from 0.5 to 2 h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a07195bc-7442-32b4-e053-2995a90a0151 (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The plasma half-life is dose-dependent and it ranges from 0.5 to 2 h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:02fb700d-a28c-4d45-b78d-382dc0d5986c (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The plasma half-life is dose-dependent and it ranges from 0.5 to 2 h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0413f511-6b34-4c15-e48b-3fad08baacbe (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The plasma half-life is dose-dependent, and it ranges from 0.5 to 2 h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eede8a0c-5ae6-4166-84b3-12081405f08e (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The plasma half-life is dose-dependent, and it ranges from 0.5 to 2 h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:88114716-5759-4bc9-8a85-d28da12962cc (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The plasma half-life is dose-dependent and it ranges from 0.5 to 2 h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:239b4816-6a55-451b-bf40-e611be07d12f (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The plasma half-life is dose-dependent and it ranges from 0.5 to 2 h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7014808d-cec9-4b2c-8eb5-940493e356ab (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The plasma half-life is dose-dependent and it ranges from 0.5 to 2 h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c4c6bc1f-e0c7-fd0d-e053-2995a90abdef (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The plasma half-life is dose-dependent and it ranges from 0.5 to 2 h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:45dc6b8b-ed5d-40a2-8d9c-084c863ae93a (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The plasma half-life is dose-dependent and it ranges from 0.5 to 2 h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c118b39-cb4e-31a9-e063-6394a90a41b0 (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The plasma half-life is dose-dependent and it ranges from 0.5 to 2 h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1c634e53-44d6-cdcd-e063-6294a90a92e9 (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The plasma half-life is dose-dependent and it ranges from 0.5 to 2 h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9ea0a519-dc7c-42e3-939e-2a7c80eedd25 (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The plasma half-life is dose-dependent and it ranges from 0.5 to 2 h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:41dd053d-49f6-4eb1-b9e7-3508ede82df8 (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The plasma half-life is dose-dependent and it ranges from 0.5 to 2 h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cb1c1e7a-c9ca-4a07-8833-e45ce436d287 (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The plasma half-life is dose-dependent and it ranges from 0.5 to 2 h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:25b0ba06-3274-4a3f-8c39-42d13764ecdf (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The plasma half-life is dose-dependent and it ranges from 0.5 to 2 h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c4fa6d34-e76b-4c3c-b74d-21ce41432a04 (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The plasma half-life is dose-dependent and it ranges from 0.5 to 2 h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9207cef5-4cec-41e7-a351-29ba726feb44 (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The plasma half-life is dose-dependent and it ranges from 0.5 to 2 h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:463e0624-b8c3-386b-e063-6294a90afd28 (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The plasma half-life is dose-dependent and it ranges from 0.5 to 2 h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6c181d7e-aed2-4975-30ac-d39a94cca7ec (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The plasma half-life is dose-dependent and it ranges from 0.5 to 2 h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9cd7abe6-3923-4007-8491-273ef6e05ad7 (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The plasma half-life is dose-dependent and it ranges from 0.5 to 2 h.
Projected row 707
- Medicine slug
- heparin
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 58
- Source count
- 53
- Agreement rate
- 1
- Recorded readings
0.07 L/kg
- Numeric value
- 0.07
- Unit
- L/kg
- Source records
- 53
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 53 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:feec2820-502f-4a97-84c9-f173729c51d3 (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The volume of distribution is 0.07 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8ebe4b4d-cb28-47e8-9598-6105d250b3d2 (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The volume of distribution is 0.07 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6be171fb-c85f-4336-a88d-b4d97bb0fe03 (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The volume of distribution is 0.07 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9a5549ae-527a-1b83-e053-2a95a90a133d (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The volume of distribution is 0.07 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7df6c90c-3b55-4bb6-8a72-6e6a6aca4e7c (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The volume of distribution is 0.07 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32e34077-aff1-4ec7-f9b0-b8e240768fb8 (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The volume of distribution is 0.07 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6d5eae7d-a5f6-411c-b589-3e5f7eecc875 (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The volume of distribution is 0.07 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a120bdfd-21e1-4024-82a7-13cfeed290c1 (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The volume of distribution is 0.07 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cece935c-1c0a-4949-b023-d6df3d53fbfa (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The volume of distribution is 0.07 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:295ea9c6-d08c-40f0-a908-de0fdac44644 (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The volume of distribution is 0.07 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1e362730-5a56-4948-a90f-2cb75fed9e91 (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The volume of distribution is 0.07 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ef309d83-7262-4874-8580-f4ca254f963a (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The volume of distribution is 0.07 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:83a59e7d-63e9-4eb8-87f0-52039d6893a5 (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The volume of distribution is 0.07 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4deaa9ac-91aa-d96b-e063-6294a90a47bd (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The volume of distribution is 0.07 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51197aa6-de34-3a55-e063-6294a90a89c9 (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The volume of distribution is 0.07 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e0cc5f44-9a67-4274-a48a-d6118e96d391 (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The volume of distribution is 0.07 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c8c4edd2-ee9e-4558-6b8c-b83adc242a0a (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The volume of distribution is 0.07 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ad0f410c-6121-43f9-9844-943472961cb0 (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The volume of distribution is 0.07 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2edf6d35-5cf3-b7ff-e063-6394a90a4f33 (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The volume of distribution is 0.07 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:62cfd1bb-894f-4429-b362-1e40981dccc6 (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The volume of distribution is 0.07 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2a173253-dfdc-4d9d-8dee-b9c13e6fa9f5 (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The volume of distribution is 0.07 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a5fab0b1-c472-489c-ba87-2f8e53356173 (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The volume of distribution is 0.07 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:07438e10-1589-4683-9f26-e5494d076cf0 (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The volume of distribution is 0.07 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:301b19bc-21c2-4a35-9d29-569b08d855c4 (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The volume of distribution is 0.07 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57f1ec87-8a7d-41da-b8b8-9ecc8601c60f (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The volume of distribution is 0.07 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:34b8fe93-ee34-4a35-9af5-5d41705a28e9 (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The volume of distribution is 0.07 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3ea2bd53-ed13-a516-e063-6394a90a5dd9 (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The volume of distribution is 0.07 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3edf9198-b88d-7808-e063-6394a90ae89c (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The volume of distribution is 0.07 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7f05762a-7527-4796-b21e-68277aec379e (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The volume of distribution is 0.07 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56dc3074-f1c5-45a3-b923-f1d14858e06d (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The volume of distribution is 0.07 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3a998729-c912-4e21-8e49-d1e72ba6fe9e (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The volume of distribution is 0.07 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f67eea4e-80ff-48da-8b04-8addc5cd31d1 (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The volume of distribution is 0.07 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0d929726-76c3-48fc-b4e7-fd06409f9fb3 (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The volume of distribution is 0.07 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a07195bc-7442-32b4-e053-2995a90a0151 (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The volume of distribution is 0.07 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:02fb700d-a28c-4d45-b78d-382dc0d5986c (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The volume of distribution is 0.07 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0413f511-6b34-4c15-e48b-3fad08baacbe (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The volume of distribution is 0.07 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eede8a0c-5ae6-4166-84b3-12081405f08e (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The volume of distribution is 0.07 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:88114716-5759-4bc9-8a85-d28da12962cc (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The volume of distribution is 0.07 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:239b4816-6a55-451b-bf40-e611be07d12f (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The volume of distribution is 0.07 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7014808d-cec9-4b2c-8eb5-940493e356ab (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The volume of distribution is 0.07 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c4c6bc1f-e0c7-fd0d-e053-2995a90abdef (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The volume of distribution is 0.07 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:45dc6b8b-ed5d-40a2-8d9c-084c863ae93a (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The volume of distribution is 0.07 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c118b39-cb4e-31a9-e063-6394a90a41b0 (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The volume of distribution is 0.07 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1c634e53-44d6-cdcd-e063-6294a90a92e9 (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The volume of distribution is 0.07 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9ea0a519-dc7c-42e3-939e-2a7c80eedd25 (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The volume of distribution is 0.07 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:41dd053d-49f6-4eb1-b9e7-3508ede82df8 (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The volume of distribution is 0.07 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cb1c1e7a-c9ca-4a07-8833-e45ce436d287 (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The volume of distribution is 0.07 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:25b0ba06-3274-4a3f-8c39-42d13764ecdf (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The volume of distribution is 0.07 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c4fa6d34-e76b-4c3c-b74d-21ce41432a04 (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The volume of distribution is 0.07 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9207cef5-4cec-41e7-a351-29ba726feb44 (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The volume of distribution is 0.07 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:463e0624-b8c3-386b-e063-6294a90afd28 (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The volume of distribution is 0.07 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6c181d7e-aed2-4975-30ac-d39a94cca7ec (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The volume of distribution is 0.07 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9cd7abe6-3923-4007-8491-273ef6e05ad7 (opens source in a new tab)
Heparin label
Version not recorded · Effective date not recorded
The volume of distribution is 0.07 L/kg.
Projected row 708
- Medicine slug
- hydralazine
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 100
- Source count
- 76
- Agreement rate
- 1
- Recorded readings
3 to 7 hours
- Numeric value
- 3
- Unit
- hours
- Source records
- 76
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 76 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3b61d1b0-c699-67a8-e054-00144ff88e88 (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydrALAZINE decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e7bfec3d-5222-4a26-8f99-6c2a28e14aa6 (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent HydrALAZINE decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:36499d4b-bcaf-4b49-aa2a-10c3e34550d0 (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydralazine decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1fd8cf42-66ae-4af5-a5ae-7c9679a0e532 (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydrALAZINE decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a862321d-ebc1-7676-e053-2995a90a5861 (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydrALAZINE decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4aa1b3e8-9389-fe2c-e063-6294a90a7fb9 (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydralazine decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:149fa857-30ad-451d-b6e2-0000483ccc97 (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydralazine decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b6ccd35e-f69c-4eef-a456-905e030ae911 (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydrALAZINE decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6c40d818-77a9-492c-b9b6-d8a0fe8d6736 (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydrALAZINE decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:162a0c00-4db8-4f8d-9686-be2f8449abd8 (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydralazine decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:63f388e0-9f3d-4902-990c-9a105aa098ad (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydrALAZINE decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:921c8693-84c2-4313-a2a6-ab3be637d554 (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent HydrALAZINE decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9892176-d4a6-4edb-92b9-5f56243f3d22 (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydralazine decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ff2c4d1e-33ee-40d7-955b-d736f0559f39 (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydralazine decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:493a8b7e-5bb1-4db2-91a7-77ed87864131 (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydralazine decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ddbbdb09-3202-42d7-bbb0-08331dde2f54 (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydralazine decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0c7f9bd0-6c0a-4521-b77a-3582faa96874 (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydrALAZINE decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f9f56326-6d72-47d3-89ac-3625b8a6d713 (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydralazine decline with a half-life of 3-7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:811831f9-a844-463a-874d-fb8407659f0b (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent HydrALAZINE decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:37ba0233-ed75-498a-a067-6220da573653 (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydralazine decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3a7562a8-2f67-4411-ac4a-ab7924193e82 (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydrALAZINE decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bc37cf50-b18d-467e-bf67-3270faa8332e (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydralazine decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51c293c1-70e7-48c7-8af1-a8b74312ed56 (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydrALAZINE decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:41c019e3-7b07-5f12-e063-6294a90a5365 (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydralazine decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:89afc8ef-27c4-489a-81de-3f8f65f6bbb8 (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydrALAZINE decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:66c5eaa4-a51a-464b-98ad-f094f32876dd (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydralazine decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:438479d0-ff61-4008-a0fc-1ee44b97cf7f (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydrALAZINE decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d2d98842-ff32-4a61-94e0-60e06919948f (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydrALAZINE decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8224aa3d-b1b9-40df-93fd-a91c6a158898 (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydralazine decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dfd60a79-2a30-41e6-b000-a144730099a8 (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydrALAZINE decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4d1594dc-376b-44bd-8c0e-5de731dfb7f9 (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydralazine decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:024ac6b8-5ce0-4435-9b11-b1806c511d7b (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydrALAZINE decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a04eefaf-ba3c-448d-8ece-4aa9ab2e3508 (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydrALAZINE decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d61ffa06-8138-4a1d-9530-095a80d9c9ce (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydrALAZINE decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e6d4b15e-1407-4783-94e4-9971dea68221 (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydralazine decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bfbd5960-ae6b-46f5-adfa-e330d7a21dfa (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydralazine decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:62475f78-5410-43c2-a11d-54a8363c3ae1 (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydralazine decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2df51a19-a39a-0ec8-e063-6394a90a147c (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydrALAZINE decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7253aaa0-e272-499f-9bfa-304e9556a8fb (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydrALAZINE decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0d65e146-83e5-427f-ac06-04c0d8e72cea (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydralazine decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:775e99c4-e18d-4648-a0e3-8709950249ff (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydrALAZINE decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:336b11da-e592-4386-921f-3c136d754f2a (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydrALAZINE decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:500b7f76-5f4e-4e7d-85c3-18b9f66d7504 (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydralazine decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:669532c9-ba15-4f4b-95a8-13782deb3521 (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydrALAZINE decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:914d5b62-6f9b-4665-8562-689367c36230 (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydralazine decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e617023e-b060-4db9-a97e-e2b11a37901e (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydralazine decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a8194ac4-02d5-4aa1-b4e4-a3759f6f64b5 (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydralazine decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f07abdec-6d94-45b6-be1b-10a898ea28c2 (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydrALAZINE decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:90c18c55-3045-4a10-a2bb-012e4a5e1564 (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydrALAZINE decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a456bc34-0c79-44f4-9119-50028a978f5f (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydrALAZINE decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:48cf71dd-19dc-4239-9117-ebcf9731a45d (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydrALAZINE decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4985994c-23ab-4409-bab6-5a17db767f13 (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydralazine decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1275dd50-d97f-2e8f-e063-6394a90a4a67 (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydrALAZINE decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:18dd864f-1e27-4c98-8f21-eaded77a3ed6 (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydralazine decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d5b0165e-9823-470a-8ed0-5c4c8722369d (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydralazine decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4b7d3378-86f8-0a5f-e054-00144ff8d46c (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydrALAZINE decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8ade1ffe-3738-4aa1-b9c7-59f7290600b9 (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydralazine decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2e9688ef-781c-aead-e063-6294a90a7bca (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydrALAZINE decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a79ddc89-546b-4808-879d-c0f592141636 (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydrALAZINE decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e9450e82-329f-4fd8-a0b3-3e8e22715965 (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydrALAZINE decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:db138daf-2d2d-4730-a621-a1bd209d5b9f (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydrALAZINE decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4671cefa-4468-4116-ba40-3d3b0f581ea1 (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydrALAZINE decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:58773e8c-b6bc-6bc6-e063-6294a90adc26 (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydrALAZINE decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a70d20d6-23f0-477e-915c-678a86782175 (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydrALAZINE decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c2638ae6-a210-490f-8389-bbed6a3229c5 (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydralazine decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d4509f69-e60e-4440-957b-5c2714480335 (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydralazine decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2e82655e-8435-46fa-b734-8e7c6e803453 (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydrALAZINE decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:10f3e76e-9bba-4151-89fb-90d823a0a68c (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydralazine decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7ae650f7-a481-4637-a9a2-9bda43a5a288 (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydralazine decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5da36930-d3da-4b5c-9e22-2b141bc01a9c (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydrALAZINE decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f16f1d87-f9e6-4555-9baf-26ff17cb1d28 (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydrALAZINE decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ada28f78-e933-7acf-e053-2995a90ae316 (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydrALAZINE decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ab1c6f37-3b64-23fb-e053-2995a90a932f (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydrALAZINE decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a1066707-2391-4918-8ded-600c017fde48 (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydrALAZINE decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b3d1786d-c3ff-42f1-a09f-37a9c9021e5a (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydrALAZINE decline with a half-life of 3 to 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:db7500f3-f8a6-46b1-bb64-9727617a9643 (opens source in a new tab)
Hydralazine label
Version not recorded · Effective date not recorded
Plasma levels of apparent hydralazine decline with a half-life of 3 to 7 hours.
Projected row 709
- Medicine slug
- hydrochlorothiazide
- Compared field
- bioavailability
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 144
- Source count
- 32
- Agreement rate
- 0.96875
- Recorded readings
10%
- Numeric value
- 10
- Unit
- %
- Source records
- 31
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 31 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:02a481cb-ad80-41bb-82d3-c237b00ed8d7 (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
When hydrochlorothiazide capsules, USP are administered with food, its bioavailability is reduced by 10%, the maximum plasma concentration is reduced by 20%, and the time to maximum concentration increases from 1.6 to 2.9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:98edae8a-99dc-4f26-a956-3ad58bf38a26 (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
When hydrochlorothiazide is administered with food, its bioavailability is reduced by 10%, the maximum plasma concentration is reduced by 20%, and the time to maximum concentration increases from 1.6 to 2.9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ef56450d-86d3-2654-e053-2995a90a142c (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
When hydrochlorothiazide capsules are administered with food, its bioavailability is reduced by 10%, the maximum plasma concentration is reduced by 20%, and the time to maximum concentration increases from 1.6 to 2.9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:39d4dbd3-8f24-4898-a240-e94e06fa229a (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
When hydrochlorothiazide is administered with food, its bioavailability is reduced by 10%, the maximum plasma concentration is reduced by 20%, and the time to maximum concentration increases from 1.6 to 2.9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bd5728a2-6322-42e3-bd1e-e4915750e398 (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
When hydrochlorothiazide capsules, USP are administered with food, its bioavailability is reduced by 10%, the maximum plasma concentration is reduced by 20%, and the time to maximum concentration increases from 1.6 to 2.9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a2de8e26-ef5a-41c7-888b-990629b11145 (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
When hydrochlorothiazide is administered with food, its bioavailability is reduced by 10%, the maximum plasma concentration is reduced by 20%, and the time to maximum concentration increases from 1.6 to 2.9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:578f74ea-53d1-4c44-b872-66033292abe0 (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
When hydrochlorothiazide is administered with food, its bioavailability is reduced by 10%, the maximum plasma concentration is reduced by 20%, and the time to maximum concentration increases from 1.6 to 2.9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:45316037-52ec-438f-8780-b2e983fef3f5 (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
When hydrochlorothiazide capsules, USP are administered with food, its bioavailability is reduced by 10%, the maximum plasma concentration is reduced by 20%, and the time to maximum concentration increases from 1.6 to 2.9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:918391e3-e8b3-4ceb-b4e7-c7c9617ea882 (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
When hydrochlorothiazide capsules, USP are administered with food, its bioavailability is reduced by 10%, the maximum plasma concentration is reduced by 20%, and the time to maximum concentration increases from 1.6 to 2.9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0f7a608d-748b-49a9-a4b3-b3fdcab53ce0 (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
When hydrochlorothiazide is administered with food, its bioavailability is reduced by 10%, the maximum plasma concentration is reduced by 20%, and the time to maximum concentration increases from 1.6 to 2.9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:911a18c1-120a-46b3-b7a8-25eb37843473 (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
When hydrochlorothiazide capsules, USP are administered with food, its bioavailability is reduced by 10%, the maximum plasma concentration is reduced by 20%, and the time to maximum concentration increases from 1.6 to 2.9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:460f922c-1fda-44a5-889e-d7009883176b (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
When hydrochlorothiazide capsules are administered with food, its bioavailability is reduced by 10%, the maximum plasma concentration is reduced by 20%, and the time to maximum concentration increases from 1.6 to 2.9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c1052d38-fd75-40c2-a685-0e889009be0b (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
When hydrochlorothiazide is administered with food, its bioavailability is reduced by 10%, the maximum plasma concentration is reduced by 20%, and the time to maximum concentration increases from 1.6 to 2.9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f0b993f2-9771-42e3-b10e-09719189e2bd (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
When hydrochlorothiazide capsules are administered with food, its bioavailability is reduced by 10%, the maximum plasma concentration is reduced by 20%, and the time to maximum concentration increases from 1.6 to 2.9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b54ec2b1-3325-46a1-b654-8a75dc41ab0a (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
When hydrochlorothiazide capsules are administered with food, its bioavailability is reduced by 10%, the maximum plasma concentration is reduced by 20%, and the time to maximum concentration increases from 1.6 to 2.9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cb7712f3-9a0b-442d-859d-8be5e6e2529a (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
When hydrochlorothiazide is administered with food, its bioavailability is reduced by 10%, the maximum plasma concentration is reduced by 20%, and the time to maximum concentration increases from 1.6 to 2.9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:13ed002f-c5bb-401c-891a-70b70cbd8fb6 (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
When hydrochlorothiazide is administered with food, its bioavailability is reduced by 10%, the maximum plasma concentration is reduced by 20%, and the time to maximum concentration increases from 1.6 to 2.9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f32ce8fe-6cbc-8a15-e053-2995a90a8eec (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
When hydrochlorothiazide capsules, USP are administered with food, its bioavailability is reduced by 10%, the maximum plasma concentration is reduced by 20%, and the time to maximum concentration increases from 1.6 to 2.9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cb7b7315-0170-492c-803f-60a6e75e55da (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
When hydrochlorothiazide capsules, USP are administered with food, its bioavailability is reduced by 10%, the maximum plasma concentration is reduced by 20%, and the time to maximum concentration increases from 1.6 to 2.9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2b21f3fc-4164-401a-803e-b982dea97e19 (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
When hydrochlorothiazide capsules, USP are administered with food, its bioavailability is reduced by 10%, the maximum plasma concentration is reduced by 20%, and the time to maximum concentration increases from 1.6 to 2.9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e3afa83d-c79c-848a-e053-2a95a90ac922 (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
When hydrochlorothiazide is administered with food, its bioavailability is reduced by 10%, the maximum plasma concentration is reduced by 20%, and the time to maximum concentration increases from 1.6 to 2.9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:69c41abb-75f4-429b-905a-1ce967924aee (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
When hydrochlorothiazide capsules, USP are administered with food, its bioavailability is reduced by 10%, the maximum plasma concentration is reduced by 20%, and the time to maximum concentration increases from 1.6 to 2.9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a3eb7294-f913-434b-896c-da028bfebc73 (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
When hydrochlorothiazide is administered with food, its bioavailability is reduced by 10%, the maximum plasma concentration is reduced by 20%, and the time to maximum concentration increases from 1.6 to 2.9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:841b7962-bf5d-4c45-b594-80b17ba5187d (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
When hydrochlorothiazide capsule is administered with food, its bioavailability is reduced by 10%; the maximum plasma concentration is reduced by 20%, and the time to maximum concentration increases from 1.6 to 2.9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d6b933c6-f5f8-406a-84d6-b22c6040482a (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
When hydrochlorothiazide capsules, USP are administered with food, its bioavailability is reduced by 10%, the maximum plasma concentration is reduced by 20%, and the time to maximum concentration increases from 1.6 to 2.9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5bacc909-6b02-4815-85ef-55fd25b1b1f7 (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
When hydrochlorothiazide is administered with food, its bioavailability is reduced by 10%, the maximum plasma concentration is reduced by 20%, and the time to maximum concentration increases from 1.6 to 2.9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0789baef-3424-43ab-a3fb-4908172da565 (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
When hydrochlorothiazide capsules, USP are administered with food, its bioavailability is reduced by 10%, the maximum plasma concentration is reduced by 20%, and the time to maximum concentration increases from 1.6 to 2.9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6a11a458-dc69-40ba-a58a-649733e0e8ab (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
When hydrochlorothiazide is administered with food, its bioavailability is reduced by 10%, the maximum plasma concentration is reduced by 20%, and the time to maximum concentration increases from 1.6 to 2.9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:34703033-14c4-459c-8b8f-2f2e1145aff7 (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
When hydrochlorothiazide capsule is administered with food, its bioavailability is reduced by 10%; the maximum plasma concentration is reduced by 20%, and the time to maximum concentration increases from 1.6 to 2.9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0fc94bc2-fa38-439a-a609-1b4130cdacb1 (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
When hydrochlorothiazide capsules are administered with food, its bioavailability is reduced by 10%, the maximum plasma concentration is reduced by 20%, and the time to maximum concentration increases from 1.6 to 2.9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ff557069-f177-4e2e-91f4-675a033e2739 (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
When hydrochlorothiazide capsules, USP are administered with food, its bioavailability is reduced by 10%, the maximum plasma concentration is reduced by 20%, and the time to maximum concentration increases from 1.6 to 2.9 hours.
85%
- Numeric value
- 85
- Unit
- %
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:41aaea48-6c1b-42c8-a96f-5923d49dc934 (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
Single doses of either cholestyramine or colestipol resins reduced the bioavailability of hydrochlorothiazide by up to 85% and 43%, respectively.
Projected row 710
- Medicine slug
- hydrochlorothiazide
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 144
- Source count
- 36
- Agreement rate
- 0.972222
- Recorded readings
6 to 15 hours
- Numeric value
- 6
- Unit
- hours
- Source records
- 35
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 35 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:02a481cb-ad80-41bb-82d3-c237b00ed8d7 (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
The plasma elimination half-life has been reported to be 6 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:98edae8a-99dc-4f26-a956-3ad58bf38a26 (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
The plasma elimination half-life has been reported to be 6 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e31bd548-29ae-419a-831a-80ebb26e042f (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
The plasma elimination half-life has been reported to be 6 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ef56450d-86d3-2654-e053-2995a90a142c (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
The plasma elimination half-life has been reported to be 6 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:39d4dbd3-8f24-4898-a240-e94e06fa229a (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
The plasma elimination half-life has been reported to be 6 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bd5728a2-6322-42e3-bd1e-e4915750e398 (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
The plasma elimination half-life has been reported to be 6 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a2de8e26-ef5a-41c7-888b-990629b11145 (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
The plasma elimination half-life has been reported to be 6 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:82ad0fdf-5d47-4c2d-883b-f28b2d3fb6b0 (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
The plas‑ma elimination half-life has been reported to be 6 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:578f74ea-53d1-4c44-b872-66033292abe0 (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
The plasma elimination half-life has been reported to be 6 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:45316037-52ec-438f-8780-b2e983fef3f5 (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
The plasma elimination half-life has been reported to be 6 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:918391e3-e8b3-4ceb-b4e7-c7c9617ea882 (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
The plasma elimination half-life has been reported to be 6 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0f7a608d-748b-49a9-a4b3-b3fdcab53ce0 (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
The plasma elimination half-life has been reported to be 6 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:911a18c1-120a-46b3-b7a8-25eb37843473 (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
The plasma elimination half-life has been reported to be 6 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:460f922c-1fda-44a5-889e-d7009883176b (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
The plasma elimination half-life has been reported to be 6 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c1052d38-fd75-40c2-a685-0e889009be0b (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
The plasma elimination half-life has been reported to be 6 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f0b993f2-9771-42e3-b10e-09719189e2bd (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
The plasma elimination half-life has been reported to be 6 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b54ec2b1-3325-46a1-b654-8a75dc41ab0a (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
The plasma elimination half-life has been reported to be 6 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cb7712f3-9a0b-442d-859d-8be5e6e2529a (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
The plasma elimination half-life has been reported to be 6 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8242c1de-f482-4a85-b977-610e71fa4904 (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
The plasma elimination half-life has been reported to be 6 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:13ed002f-c5bb-401c-891a-70b70cbd8fb6 (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
The plasma elimination half-life has been reported to be 6 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f32ce8fe-6cbc-8a15-e053-2995a90a8eec (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
The plasma elimination half-life has been reported to be 6 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cb7b7315-0170-492c-803f-60a6e75e55da (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
The plasma elimination half-life has been reported to be 6 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2b21f3fc-4164-401a-803e-b982dea97e19 (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
The plasma elimination half-life has been reported to be 6 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e3afa83d-c79c-848a-e053-2a95a90ac922 (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
The plasma elimination half-life has been reported to be 6 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:69c41abb-75f4-429b-905a-1ce967924aee (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
The plasma elimination half-life has been reported to be 6 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a3eb7294-f913-434b-896c-da028bfebc73 (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
The plasma elimination half-life has been reported to be 6 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:841b7962-bf5d-4c45-b594-80b17ba5187d (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
The plasma elimination half-life has been reported to be 6 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d6b933c6-f5f8-406a-84d6-b22c6040482a (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
The plasma elimination half-life has been reported to be 6 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5bacc909-6b02-4815-85ef-55fd25b1b1f7 (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
The plasma elimination half-life has been reported to be 6 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0789baef-3424-43ab-a3fb-4908172da565 (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
The plasma elimination half-life has been reported to be 6 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6a11a458-dc69-40ba-a58a-649733e0e8ab (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
The plasma elimination half-life has been reported to be 6 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:34703033-14c4-459c-8b8f-2f2e1145aff7 (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
The plasma elimination half-life has been reported to be 6 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0fc94bc2-fa38-439a-a609-1b4130cdacb1 (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
The plasma elimination half-life has been reported to be 6 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ff557069-f177-4e2e-91f4-675a033e2739 (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
The plasma elimination half-life has been reported to be 6 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:33f9c3ae-108d-469e-af6c-8be3b0f83139 (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
The plasma elimination half-life has been reported to be 6 to 15 hours.
10 hours
- Numeric value
- 10
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:41aaea48-6c1b-42c8-a96f-5923d49dc934 (opens source in a new tab)
Hydrochlorothiazide label
Version not recorded · Effective date not recorded
Elimination Following oral administration of INZIRQO, plasma hydrochlorothiazide concentrations decline biexponentially, with a terminal elimination half-life of about 10 hours.
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=700Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.